istock-866149824natee-meepian
Natee Meepian / iStockphoto.com
12 October 2018Americas

AbbVie secures another Humira settlement

AbbVie has announced yet another settlement relating to litigation over Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 August 2018   AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.
Americas
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
3 January 2020   California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

More on this story

Americas
13 August 2018   AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.
Americas
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
3 January 2020   California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

More on this story

Americas
13 August 2018   AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.
Americas
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
3 January 2020   California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.